Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

26.10
+0.12000.46%
Post-market: 26.100.00000.00%19:30 EDT
Volume:1.18M
Turnover:31.06M
Market Cap:4.87B
PE:-7.79
High:26.87
Open:26.22
Low:26.02
Close:25.98
52wk High:27.31
52wk Low:11.92
Shares:186.58M
Float Shares:186.00M
Volume Ratio:0.71
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:6.94
PE(LYR):-7.51

Loading ...

Stock Track | Dyne Therapeutics Plummets 5.03% Intraday After Price Target Cut

Stock Track
·
May 16

Dyne Therapeutics price target lowered to $33 from $34 at Evercore ISI

TIPRANKS
·
May 15

Piper Sandler Remains a Buy on Dyne Therapeutics (DYN)

TIPRANKS
·
May 14

Dyne Therapeutics Is Maintained at Market Perform by Bernstein

Dow Jones
·
May 14

Dyne Therapeutics to join RBC Capital Markets healthcare conference fireside chat

Reuters
·
May 13

Dyne Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 13

Dyne Therapeutics price target raised to $24 from $23 at Bernstein

TIPRANKS
·
May 13

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Dyne Therapeutics (DYN)

TIPRANKS
·
May 13

Dyne Can Unlock Value in Two Drug Prospects, RBC Says

MT Newswires Live
·
May 13

Dyne Therapeutics reports Q1 EPS (73c), consensus (78c)

TIPRANKS
·
May 12

Dyne Therapeutics Q1 EPS $(0.73) Beats $(0.78) Estimate

Benzinga Earnings
·
May 11

Dyne Therapeutics Q1 adjusted EPS beats expectations on lower expenses

Reuters
·
May 11

Earnings Flash (DYN) Dyne Therapeutics Posts Q1 Loss $0.73 a Share, vs. FactSet Est of $0.74 Loss

MT Newswires Live
·
May 11

Dyne Therapeutics Q1 Operating Expenses USD 125.276 Million

THOMSON REUTERS
·
May 11

Dyne Therapeutics Q1 EPS USD -0.73 VS. Ibes Estimate USD -0.77

THOMSON REUTERS
·
May 11

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewswire
·
May 11

Dyne Therapeutics Q1 net loss widens to $120.9 million

Reuters
·
May 11

Dyne Therapeutics director Jason P. Rhodes disposes of common shares worth $1.94 million

Reuters
·
May 07

Dyne Therapeutics director Jason P. Rhodes disposes of shares worth $4.18 million

Reuters
·
May 01

Dyne Therapeutics Director Jason P. Rhodes disposes of $6.76 million in shares

Reuters
·
Apr 28